- Home
- RERE vs UPB Comparison
RERE vs UPB Comparison
Compare RERE & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RERE
- UPB
- Stock Information
- Founded
- RERE 2011
- UPB 2021
- Country
- RERE China
- UPB United States
- Employees
- RERE N/A
- UPB N/A
- Industry
- RERE Other Specialty Stores
- UPB
- Sector
- RERE Consumer Discretionary
- UPB
- Exchange
- RERE Nasdaq
- UPB NYSE
- Market Cap
- RERE 444.1M
- UPB 521.3M
- IPO Year
- RERE 2021
- UPB 2024
- Fundamental
- Price
- RERE $2.90
- UPB $10.88
- Analyst Decision
- RERE
- UPB Strong Buy
- Analyst Count
- RERE 0
- UPB 4
- Target Price
- RERE N/A
- UPB $56.50
- AVG Volume (30 Days)
- RERE 759.2K
- UPB 422.3K
- Earning Date
- RERE 08-19-2025
- UPB 08-14-2025
- Dividend Yield
- RERE N/A
- UPB N/A
- EPS Growth
- RERE N/A
- UPB N/A
- EPS
- RERE 0.07
- UPB N/A
- Revenue
- RERE $2,388,301,386.00
- UPB $2,296,000.00
- Revenue This Year
- RERE $27.37
- UPB N/A
- Revenue Next Year
- RERE $24.06
- UPB N/A
- P/E Ratio
- RERE $40.03
- UPB N/A
- Revenue Growth
- RERE 26.09
- UPB N/A
- 52 Week Low
- RERE $2.00
- UPB $5.14
- 52 Week High
- RERE $3.70
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- RERE 63.02
- UPB N/A
- Support Level
- RERE $2.64
- UPB N/A
- Resistance Level
- RERE $2.89
- UPB N/A
- Average True Range (ATR)
- RERE 0.14
- UPB 0.00
- MACD
- RERE 0.03
- UPB 0.00
- Stochastic Oscillator
- RERE 73.13
- UPB 0.00
About RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.